Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.

Abstract

6013 Background: Lenvatinib (LEN), an oral multikinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT, significantly prolonged progression-free survival (PFS) vs placebo in the phase 3 SELECT...